Home › Streamline And Accelerate A Drug Development Plan Using The 505(b)(2) Pathway
 

Keywords :   


Streamline And Accelerate A Drug Development Plan Using The 505(b)(2) Pathway

2013-02-19 11:49:02| drugdiscoveryonline Downloads

An international pharmaceutical company approached Camargo Pharmaceutical Services to help navigate the Food and Drug Administration (FDA) 505(b)(2) approval pathway for a promising drug under development designated for patients with cardiovascular disease. Product X is a prodrug that is converted in one metabolism-dependent step to produce the active metabolite of an approved drug.

Tags: plan development drug pathway

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10Hurricane Milton Potential Storm Surge Flooding Map
06.10Hurricane Milton Probabilistic Storm Surge Graphics
06.10Hurricane Milton Graphics
06.10Hurricane Milton Forecast Discussion Number 6
06.10Hurricane Milton Wind Speed Probabilities Number 6
06.10Hurricane Milton Public Advisory Number 6
06.10Summary for Hurricane Milton (AT4/AL142024)
06.10Hurricane Kirk Graphics
More »